Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DO-IT trial of intravenous thrombolysis in acute ischemic stroke patients with recent DOAC use
NL-OMON59685Phase 4Recruiting
- Sponsor
- Insel Gruppe
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tissue-plasminogen activator and tenecteplase in ischemic stroke (2 arms), sponsored by Insel Gruppe. Primary endpoint: Modified Rankin Scale shift at 90 days. Started Sep 2025; status: recruiting.
02
Drugs
tissue-plasminogen activatortenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NL-OMON59685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59685.